1517 related articles for article (PubMed ID: 15241829)
1. Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy.
Bonnet F; Lewden C; May T; Heripret L; Jougla E; Bevilacqua S; Costagliola D; Salmon D; Chêne G; Morlat P
Cancer; 2004 Jul; 101(2):317-24. PubMed ID: 15241829
[TBL] [Abstract][Full Text] [Related]
2. Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area.
Martínez E; Milinkovic A; Buira E; de Lazzari E; León A; Larrousse M; Loncá M; Laguno M; Blanco JL; Mallolas J; García F; Miró JM; Gatell JM
HIV Med; 2007 May; 8(4):251-8. PubMed ID: 17461853
[TBL] [Abstract][Full Text] [Related]
3. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
Wong KH; Chan KC; Lee SS
Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
[TBL] [Abstract][Full Text] [Related]
4. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy.
Clifford GM; Polesel J; Rickenbach M; Dal Maso L; Keiser O; Kofler A; Rapiti E; Levi F; Jundt G; Fisch T; Bordoni A; De Weck D; Franceschi S;
J Natl Cancer Inst; 2005 Mar; 97(6):425-32. PubMed ID: 15770006
[TBL] [Abstract][Full Text] [Related]
5. Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin.
Martín-Carbonero L; Palacios R; Valencia E; Saballs P; Sirera G; Santos I; Baldobí F; Alegre M; Goyenechea A; Pedreira J; González del Castillo J; Martínez-Lacasa J; Ocampo A; Alsina M; Santos J; Podzamczer D; González-Lahoz J;
Clin Infect Dis; 2008 Aug; 47(3):410-7. PubMed ID: 18582203
[TBL] [Abstract][Full Text] [Related]
6. Factors associated with the occurrence of AIDS-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: Aquitaine Cohort, France.
Bonnet F; Balestre E; Thiébaut R; Morlat P; Pellegrin JL; Neau D; Dabis F;
Clin Infect Dis; 2006 Feb; 42(3):411-7. PubMed ID: 16392091
[TBL] [Abstract][Full Text] [Related]
7. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study.
Hung CC; Chen MY; Hsieh SM; Hsiao CF; Sheng WH; Chang SC
Vaccine; 2004 May; 22(15-16):2006-12. PubMed ID: 15121313
[TBL] [Abstract][Full Text] [Related]
8. HIV-associated monoclonal gammopathy: a retrospective analysis of 25 patients.
Amara S; Dezube BJ; Cooley TP; Pantanowitz L; Aboulafia DM
Clin Infect Dis; 2006 Nov; 43(9):1198-205. PubMed ID: 17029142
[TBL] [Abstract][Full Text] [Related]
9. AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy.
Cheung MC; Pantanowitz L; Dezube BJ
Oncologist; 2005; 10(6):412-26. PubMed ID: 15967835
[TBL] [Abstract][Full Text] [Related]
10. Causes of death of HIV-infected persons in Ottawa, Ontario, 1984-1995.
Kravcik S; Hawley-Foss N; Victor G; Angel JB; Garber GE; Pagé S; Denommé N; O'Reilly L; Cameron DW
Arch Intern Med; 1997 Oct; 157(18):2069-73. PubMed ID: 9382662
[TBL] [Abstract][Full Text] [Related]
11. [Epidemiology of HIV-associated malignancies].
Launay O; Guillevin L
Bull Cancer; 2003 May; 90(5):387-92. PubMed ID: 12850760
[TBL] [Abstract][Full Text] [Related]
12. Changes in mortality related to human immunodeficiency virus infection: comparative analysis of inpatient deaths in 1995 and in 1999-2000.
Jain MK; Skiest DJ; Cloud JW; Jain CL; Burns D; Berggren RE
Clin Infect Dis; 2003 Apr; 36(8):1030-8. PubMed ID: 12684916
[TBL] [Abstract][Full Text] [Related]
13. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
[TBL] [Abstract][Full Text] [Related]
14. Effect of maintaining highly active antiretroviral therapy on AIDS events among patients with late-stage HIV infection and inadequate response to therapy.
Gandhi T; Wei W; Amin K; Kazanjian P
Clin Infect Dis; 2006 Mar; 42(6):878-84. PubMed ID: 16477568
[TBL] [Abstract][Full Text] [Related]
15. Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma.
Zoufaly A; Stellbrink HJ; Heiden MA; Kollan C; Hoffmann C; van Lunzen J; Hamouda O;
J Infect Dis; 2009 Jul; 200(1):79-87. PubMed ID: 19476437
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic approaches to AIDS-related malignancies.
Berretta M; Cinelli R; Martellotta F; Spina M; Vaccher E; Tirelli U
Oncogene; 2003 Sep; 22(42):6646-59. PubMed ID: 14528290
[TBL] [Abstract][Full Text] [Related]
17. [AIDS associated cancers in the era of highly active antiretroviral therapy (HAART)].
Tserenpuntsag B; Kołacińska A; Jabłonowska E
Przegl Epidemiol; 2007; 61(3):529-34. PubMed ID: 18069390
[TBL] [Abstract][Full Text] [Related]
18. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
[TBL] [Abstract][Full Text] [Related]
19. HIV infection and cancer in the era of highly active antiretroviral therapy (Review).
Barbaro G; Barbarini G
Oncol Rep; 2007 May; 17(5):1121-6. PubMed ID: 17390054
[TBL] [Abstract][Full Text] [Related]
20. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy.
Viani RM; Araneta MR; Deville JG; Spector SA
Clin Infect Dis; 2004 Sep; 39(5):725-31. PubMed ID: 15356789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
